CMPS Hits Record High, RVV Breaking Out!

Psychedelics industry bellwether Compass Pathways (CMPS) gained $6.62 or 16.21% today to finish at a new all-time high closing price of $47.45 per share! We consider Revive Therapeutics (CSE: RVV) to be the #1 highest quality small-cap psychedelic biotech play. RVV is beginning to breakout big and has enormous short-term upside potential. RVV is well positioned to capitalize on the legalization of psilocybin in Oregon with their psilocybin platform technology which allows psilocybin to be delivered in therapeutic doses through thin film strips.

RVV recently announced that it has entered into a Clinical Trial Agreement with the Board of Regents of the University of Wisconsin System to conduct a clinical study entitled “Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder.”

Past performance is not an indicator of future returns. Psychstocks is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The parent company of Psychstocks has been compensated by RVV USD$30,000 cash for a six-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.

Become a Member of Psychstocks for FREE

Holler Box